AbbVie Names Robert A. Michael as Chief Executive Officer

AbbVie announced that Robert A. Michael will take the helm as the company's next Chief Executive Officer (CEO), succeeding Richard A. Gonzalez. This transition is set to take effect on July 1, 2024, marking a new chapter in the company's history.

Richard A. Gonzalez, who has been at the forefront of AbbVie's journey since its inception in 2013, will step down from his role as CEO to assume the position of Executive Chairman of the Board of Directors. During his tenure, Gonzalez has been instrumental in steering AbbVie through various milestones, including significant acquisitions and the development of a diversified business strategy that has positioned the company as a leader in the pharmaceutical sector.

Robert A. Michael, AbbVie's current President and Chief Operating Officer, will also join the Board of Directors, reflecting the board's confidence in his leadership capabilities. "On behalf of AbbVie's board, I am extremely excited that Rob has agreed to serve as AbbVie's next CEO," Gonzalez remarked, highlighting Michael's substantial contributions to the company. From establishing a robust financial planning organization to navigating the challenges post-Humira exclusivity in the U.S., Michael's role has been pivotal in shaping AbbVie's strategic direction.

Michael's tenure at AbbVie has been marked by his involvement in key business development opportunities, including the strategic acquisitions of Allergan and ImmunoGen, as well as the pending transaction with Cerevel Therapeutics. These moves have been critical to AbbVie's long-term growth strategy, underscoring Michael's vision and execution capabilities.

Expressing his gratitude and anticipation for the future, Michael stated, "I am honored to assume the CEO role for AbbVie, and I am excited about our company's bright future." He also paid tribute to Gonzalez's mentorship and leadership, acknowledging the lasting impact it will have on AbbVie.